title: Subcutaneous-PCA: an alternative to IV-PCA for postoperative pain management.
abstract: Patients (n = 120) undergoing major orthopedic (e.g., total hip replacement), urologic (e.g., radical prostatectomy), or gynecologic (e.g., total abdominal hysterectomy) procedures were randomly assigned to receive either morphine or oxymorphone postoperatively using a patient-controlled analgesic (PCA) delivery system. The opioid analgesic was administered either intravenously (IV-PCA) or subcutaneously (SQ-PCA) during the 72-h study period. Oxymorphone, 0.65 +/- 0.42 mg/h (0-24 h), 0.53 +/- 0.35 mg/h (24-48 h), and 0.42 +/- 0.31 mg/h (48-72 h), was as effective as morphine, 2.2 +/- 1.6 mg/h (0-24 h), 1.6 +/- 1.2 mg/h (24-48 h), and 1.2 +/- 1.1 mg/h (48-72 h), in providing postoperative pain relief (mean values +/- SD). Although the average opioid dosage requirements were 10 to 28% higher with SQ-PCA, it is an acceptable alternative to conventional IV-PCA for pain control after major surgical procedures. Postoperative analgesia scores and patient satisfaction were similar in all four PCA treatment groups. Thus, SQ-PCA with either oxymorphone or morphine represents a clinically acceptable alternative to IV-PCA in the treatment of postoperative pain.
authors: Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri.
authors: P F
authors: PF
authors: White
mesh_terms: D000328:Adult; D000368:Aged; D016058:Analgesia, Patient-Controlled; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010111:Oxymorphone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010149:Postoperative Pain / Q000188:drug therapy*
chemical_list: D009020:Morphine; D010111:Oxymorphone